A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combinatio… (NCT07589608) | Clinical Trial Compass
RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
United States400 participantsStarted 2026-05-15
Plain-language summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* See Master Protocol CWMM (NCT06143956) for inclusion criteria
Exclusion Criteria:
In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
* Have type 1 diabetes or type 2 diabetes
* Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
* Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
* Have a history of acute or chronic pancreatitis
* All concomitant medications should be at a stable dose for at least 3 months prior to screening
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This is a Phase 2 trial testing two drugs — macupatide and eloralintide — that I haven't heard of before; what do we know so far about their safety profile, and what unknowns should I be aware of before considering a study like this?
2Since this trial isn't recruiting yet, how long do you think it might realistically be before enrollment opens, and would waiting for it delay any other treatment options that could help me now?
3The trial is testing these two drugs both alone and in combination — does that mean some participants might receive a combination that's even less studied, and how would that affect what we know about risks compared to taking just one of them?
4Given that the main thing being measured is percent change in body weight, how does that goal line up with my specific health situation, and are there other outcomes — like blood pressure or metabolic markers — that would be equally important for me personally?
5Are there standard obesity treatments I should try first while this trial is still in the preparation stage, or would starting something now affect my eligibility if I wanted to discuss this study with you later?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percent Change from Baseline in Body Weight
Timeframe: Baseline, Week 36
Trial details
NCT IDNCT07589608
SponsorEli Lilly and Company
Sponsor typeINDUSTRY
Study typeINTERVENTIONAL
Primary completion2027-09
Contact for this trial
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or